Peptides that bind to the erythropoietin receptor

Details Peptides that bind to the erythropoietin receptor Peptides that bind to the erythropoietin receptor

2008-07-11

2010-12-21

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C930S090000, C424S001410

Reexamination Certificate

active

07855175

ABSTRACT:
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4677195 (1987-06-01), Hewick et al.
patent: 5278065 (1994-01-01), D'Andrea et al.
patent: 5292654 (1994-03-01), Yoshimura et al.
patent: 5378808 (1995-01-01), D'Andrea et al.
patent: 5441868 (1995-08-01), Lin
patent: 5547933 (1996-08-01), Lin
patent: 5580853 (1996-12-01), Sytkowski
patent: 5614184 (1997-03-01), Sytkowski et al.
patent: 5618698 (1997-04-01), Lin
patent: 5621080 (1997-04-01), Lin
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5668110 (1997-09-01), Barrett et al.
patent: 5677280 (1997-10-01), Barrett et al.
patent: 5683983 (1997-11-01), Barrett et al.
patent: 5747446 (1998-05-01), Sytkowski
patent: 5756349 (1998-05-01), Lin
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5919758 (1999-07-01), Sytkowski
patent: 5932546 (1999-08-01), Barrett et al.
patent: 5955422 (1999-09-01), Lin
patent: 5986047 (1999-11-01), Wrighton et al.
patent: 6048971 (2000-04-01), Sytkowski et al.
patent: 6077939 (2000-06-01), Wei et al.
patent: 6083913 (2000-07-01), Dower et al.
patent: 6103879 (2000-08-01), Chaovapong et al.
patent: 6107272 (2000-08-01), Sytkowski
patent: 6113906 (2000-09-01), Greenwald et al.
patent: 6121238 (2000-09-01), Dower et al.
patent: 6153407 (2000-11-01), Sytkowski et al.
patent: 6221608 (2001-04-01), Middleton et al.
patent: 6251864 (2001-06-01), Dower et al.
patent: 6333031 (2001-12-01), Olsson et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6465430 (2002-10-01), Dower et al.
patent: 6489293 (2002-12-01), Sytkowski et al.
patent: 6506362 (2003-01-01), Dower et al.
patent: 6531121 (2003-03-01), Brines et al.
patent: 6552008 (2003-04-01), Duffy et al.
patent: 6552167 (2003-04-01), Rose
patent: 6583272 (2003-06-01), Bailon
patent: 6660843 (2003-12-01), Feige et al.
patent: 7084245 (2006-08-01), Holmes et al.
patent: 2002/0015691 (2002-02-01), Greenwald et al.
patent: 2002/0037841 (2002-03-01), Papadimitriou et al.
patent: 2002/0052317 (2002-05-01), Itri et al.
patent: 2002/0086816 (2002-07-01), Brines et al.
patent: 2002/0115833 (2002-08-01), Burg et al.
patent: 2002/0160013 (2002-10-01), Olsson et al.
patent: 2002/0169128 (2002-11-01), Sigounas et al.
patent: 2002/0177166 (2002-11-01), Guthridge et al.
patent: 2003/0009018 (2003-01-01), Maeda et al.
patent: 2003/0050269 (2003-03-01), Escary
patent: 2003/0083251 (2003-05-01), Westenfelder
patent: 2003/0083361 (2003-05-01), Luengo et al.
patent: 2003/0104988 (2003-06-01), Brines et al.
patent: 2003/0120045 (2003-06-01), Bailon
patent: 2003/0125262 (2003-07-01), Kiessling et al.
patent: 2003/0134798 (2003-07-01), Brines et al.
patent: 2003/0191291 (2003-10-01), Kochendoerfer et al.
patent: 0 400 472 (1990-12-01), None
patent: 90/12874 (1990-11-01), None
patent: 92/16221 (1992-10-01), None
patent: 92/16555 (1992-10-01), None
patent: 96/40189 (1996-12-01), None
patent: 96/40749 (1996-12-01), None
patent: 96/40750 (1996-12-01), None
patent: 96/40772 (1996-12-01), None
patent: 98/25965 (1997-12-01), None
patent: 00/12587 (2000-03-01), None
patent: 00/24770 (2000-05-01), None
patent: 00/24782 (2000-05-01), None
patent: 00/33881 (2000-06-01), None
patent: 01/38342 (2001-05-01), None
patent: 01/91780 (2001-12-01), None
patent: 02/065988 (2002-08-01), None
patent: 2004/014424 (2004-02-01), None
patent: 2004/100997 (2004-11-01), None
patent: 2004/101600 (2004-11-01), None
patent: 2004/101606 (2004-11-01), None
patent: 2004/101611 (2004-11-01), None
patent: 2004/108070 (2004-12-01), None
Abuchowski, A.,et al., “Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase,” J. Biol. Chem, vol. 252, pp. 3582-3586 (1977).
Beauchamp, C.O., et al., “A new procedure for the synthesis of polytheylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin”, Anal Biochem., vol. 131, pp. 25-33 (1983).
Chen, R.H., et al., “Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)”, Biochem. Biophys. Acta., vol. 660, pp. 293-298 (1981).
Francis, G.E., et al., “PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques”, Int. J. Hematol, vol. 68, pp. 1-18 (1998).
Greenwald, R.B., et al. (2003) Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination. Bioconjug. Chem. 14:395-403.
Greenwald, R.B., et al. (2003) Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55:217-250.
Johnson et al., “Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1”, Biochemistry 37: 3699-3710 (1998).
Johnson, D.L., et al., “Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity”, Chem. Biol., vol. 4, pp. 939-950 (1997).
Kita, Y., et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma”, Dr. Des. Deliv. vol. 6, pp. 157-67 (1990).
Knauf, M.J., et al., “Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers”, J. Biol. Chem., vol. 263, pp. 15064-15070 (1988).
Lee, J.W., et al., “Reduction of azides to primary amines in substrates bearing labile ester functionality. Synthesis of a PEG-solubilized, “Y”-shaped iminodiacetic acid reagent for preparation of folate-tethered drugs”, Org. Lett, vol. 1, pp. 179-181 (1999).
Saifer, M.G., et al., “Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35,000 to 120,000 dalton poly-ethylene glycol”, Adv. Exp. Med. Biol. vol. 366, pp. 377-387 (1994).
Sasaki, et al., “Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA”, Journal of Biological Chemistry 262:12059-12076 (1987).
Somack, R., et al., “Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41,000-72,000 daltons)”, Free. Radic. Res. Commun. vols. 12-13, pp. 553-562 (1991).
Tsutsumi, Y. et al., “Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity”, J. Controlled Release, vol. 33, pp. 447 (1995).
Veronese, F. M., “Peptide and protein PEGylation: a review of problems and solutions”, Biomaterials 22:405-417 (2001).
Woller, N. C. et al., “The lectin-binding propertiesof six generations of mannose-functionaled dendrimers”, Organic Letters 4:7-10 (2002).
Wrighton et al., “Small peptides as potent mimetics of the protein hormone erythropoietin”, Science 273:458-463 (1996).
Wrighton, N.C. et al., “Increased potency of an erythropoietin peptide mimetic through covalent dimerization”, Nature Biotechology 15:1261-1265 (1997).

Affiliated with

Also associated with

Rating

Peptides that bind to the erythropoietin receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides that bind to the erythropoietin receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides that bind to the erythropoietin receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4163155